NasdaqGM:EYPTPharmaceuticals
EyePoint (EYPT) Completes Phase 3 Enrollment Early, Is The Stock Still Cheap?
EyePoint (EYPT) has just hit a key clinical milestone that puts fresh attention on its stock. The company completed enrollment ahead of schedule in its global Phase 3 COMO and CAPRI trials for DURAVYU in diabetic macular edema.
See our latest analysis for EyePoint.
The DURAVYU update comes after a sharp 8.26% 1 day share price return and 13.39% 7 day share price return, although the share price is still down 20.54% year to date while the 1 year total shareholder return is 35.78%. This...